increasing duration of median survival was achieved with combination chemotherapy. Radiation therapy of the primary tumour site and mediastinum was commonly added before or between chemotherapy cycles in an attempt to improve tumour control at the primary site. A decade later it is proving difficult to improve the duration of survival with currently available medication and further advances will depend on the emergence of new agents and approaches as a result of the great increase in our understanding of the biology of the tumour.
In studies of unselected None of these approaches has yet made a major impact. Newer agents such as etoposide, teniposide, ifosfamide, cisplatin, and carboplatin have been shown to be highly active as single agents or in combination (for example, etoposide and cisplatin). These drugs are used in many chemotherapy regimens, but no consistent improvement in median or long term survival has yet been found in unselected cases.
There has been a disappointing lack of impact from the addition of radiotherapy to chemotherapy. Although radiotherapy reduces the likelihood of recurrence at the primary site, it has had little effect on survival because chemotherapy has not controlled disseminated disease adequately. Despite different dose schedules for radiotherapy and attempts to administer the treatment at different stages during the course of chemotherapy, the effect on survival in large studies is small. 7 In view of this lack of progress, some recent studies have assessed the optimal duration of administration of chemotherapy. Undoubtedly most patients respond to chemotherapy with considerable improvement in terms of presenting symptoms and of measures that attempt to assess the quality of life. Most patients, however, especially the majority who have extensive disease, obtain only short remissions before disease progression and death. The balance between effective treatment and minimal toxicity is therefore crucial.
Several studies have addressed the question of the value of maintenance chemotherapy after an initial response, and also the length of initial chemotherapy with or without further chemotherapy when relapse occurs. In 1984 Feld et al8 published two sequential non-randomised studies. The first was concerned with 147 patients treated by three courses of cyclophosphamide, Adriamycin (doxorubicin), and vincristine (CAV); thoracic irradiation; and then a year of maintenance chemotherapy with lomustine, procarbazine, and methotrexate. Their second study was of 320 patients (153 limited disease and 167 extensive disease) treated by six courses of CAV and thoracic irradiation but no maintenance chemotherapy. In the latter study the median survival time was 49 weeks for limited disease and 34 weeks for extensive disease, similar to survival in the initial study, which included one year of maintenance chemotherapy.
Two large randomised studies on the duration of chemotherapy have recently been published. Our group9 randomised 616 patients to receive either four or eight courses of chemotherapy and at relapse to receive either symptomatic treatment or further chemotherapy using agents other than those used for initial chemotherapy. The study showed that patients allocated to receive four courses of initial chemotherapy only (with no further chemotherapy at relapse) had a median survival of 30 weeks. This was significantly inferior to the other three treatment arms, which had median survivals of 39-42 weeks. The difference was greater for the responding populations. We concluded that if only four courses of chemotherapy were given there was a survival disadvantage unless patients received chemotherapy at relapse, but if eight courses were given initially then there was no advantage in further chemotherapy at relapse. The policy of chemotherapy on relapse was, however, difficult to achieve because patients and physicians were reluctant to start chemotherapy again.
In the Medical Research Council (MRC) study'0 497 patients were given six cycles of a four drug regimen with additional radiotherapy for responding patients with limited disease between courses 2 and 3. At the completion of the initial six cycles patients whose disease remained controlled were randomly allocated to two groups, receiving either no further chemotherapy or six further courses of the same drugs but at slightly longer intervals (four weeks instead of three weeks). The overall response rate was 66%, similar to that of our study (61 %). The median survival of all patients entered was also 39 weeks. There was no overall survival advantage for patients who received the maintenance treatment, though for the 97 patients who were complete responders after initial chemotherapy there was a suggestion of longer survival with maintenance treatment-42 weeks from entry to the study against 30 weeks for those not given maintenance chemotherapy. An attempt was made in a small proportion of the patients to assess the quality of their lives during treatment. This suggested that maintenance treatment was associated with toxicity and side effects, as assessed by physician and patient, and with a poorer quality of life.
Few studies have addressed the question of quality of life during chemotherapy and afterwards. A further study by our group evaluated eight measures designed to assess the quality of life and compared them in patients receiving four and eight cycles during the second part of the treatment, when they were receiving courses 5-8 or no further treatment. All the quality of life measures showed deterioration during courses 5-8, increasingly so as treatment progressed. This adverse consequence of the second four courses of chemotherapy, however, has to be set against the longer median survival seen with eight courses of chemotherapy than with four courses. In a separate study chemotherapy also showed a considerable initial benefit in terms of quality What conclusions can be gleaned from these studies? It would seem reasonable to conclude that around six courses of chemotherapy is a reasonable optimum duration for initial chemotherapy and that maintenance chemotherapy, or further treatment at relapse, is not useful. The question still remains of whether all patients with small cell lung cancer should be treated for this period. For patients presenting with extensive disease this would appear to be a reasonable decision. The median survival would be acceptable by current standards, as would toxicity and the effects on quality of life. The MRC Lung Cancer Working Party is currently evaluating three versus six courses of chemotherapy, though to judge from our study, where four courses appeared less than optimal in terms of median survival, three courses are unlikely to be as effective as six.
Should all patients with limited disease now be offered short duration chemotherapy? More aggressive treatment of patients with limited disease and smaller tumour volume has not yet been shown to prolong survival. New drugs and new methods of intensification of treatment may prolong survival in patients with a good prognosis and these are being explored by several groups; but until these treatments have been assessed in controlled trials there appears to be no benefit in prolonging chemotherapy in small cell lung cancer, even in those with limited disease.
